Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV7IM6)

• Drug Name: Histamine Phosphate Drug Info
• Synonyms: Histamine acid phosphate; Histamine biphosphate; Histamine dihydrogen phosphate; Histamine diphosphate; Histamine phosphate [USP]; Histamine positive; H0147; Histamine phosphate (TN); Histamine phosphate (USP); Histamine phosphate (1:2); 1H-Imidazole-4-ethanamine, phosphate (1:2); 2-Imidazol-4-ylethylamine orthophosphoric acid (1:2); 4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate); 4-(2-Aminoethyl)imidazole di-acid phosphate; 4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate

Indication

Disease Entry	ICD 11	Status	REF
Diagnostic imaging	N.A.	Approved	[1]
Osteoarthritis	FA00-FA05	Approved	[2]

• Therapeutic Class: Diagnostic Agents
• Cross-matching ID:
  PubChem CID: 65513
  ChEBI ID: CHEBI:51193
  CAS Number: CAS 51-74-1
  TTD Drug ID: DMV7IM6

Molecule-Related Drug Atlas

Drug(s) Targeting Histamine receptor (HR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Repirinast	DM6KI0D	Asthma	CA23	Approved	[5]
Levomequitazine	DMAYC76	Seasonal allergic rhinitis	CA08.01	Phase 3	[6]
ETX-9101	DMZOA2L	Asthma	CA23	Phase 2	[7]
LCB-2183	DMY4IWC	Asthma	CA23	Phase 2	[8]
ETS-6218	DMV96BY	Fibromyalgia	MG30.01	Phase 2	[7]
Votucalis	DMW4LTI	Allergic rhinitis	CA08.0	Phase 2	[9]
OX-NLA	DMPEHBJ	Allergic rhinitis	CA08.0	Discontinued in Phase 3	[10]
Tesmilifene	DMPB36I	Breast cancer	2C60-2C65	Discontinued in Phase 2	[11]
CP-118	DMNJD9H	Allergic rhinitis	CA08.0	Discontinued in Phase 2	[12]
REV-598	DM314CZ	Carcinoid syndrome	5B10	Terminated	[13]

Drug(s) Affected By Tissue factor (F3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[14]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[15]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[16]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[17]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[18]
Fructose	DM43AN2	Vomiting	MD90	Approved	[19]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[4]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine receptor (HR)	TT7CXIM	NOUNIPROTAC	Modulator	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Tissue factor (F3)	OT3MSU3B	TF_HUMAN	Gene/Protein Processing	[4]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 000734.
• [2] Histamine Phosphate FDA Label
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
• [5] Mechanism of action of MY-1250, an active metabolite of Repirinast, in inhibiting histamine release from rat mast cells. Br J Pharmacol. 1992 Mar;105(3):587-90.
• [6] Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.
• [7] Clinical pipeline report, company report or official report of e-Therapeutics.
• [8] LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Int J Immunopharmacol. 1994 Aug;16(8):675-83.
• [9] CA patent application no. 520580, Histamine binding compounds for treatment method for disease conditions mediated by neutrophils.
• [10] Clinical pipeline report, company report or official report of Orexo.
• [11] Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol. 2010 Aug;62(8):1084-8.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025139)
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016819)
• [14] Inhibition of interleukin-1-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2. Oncotarget. 2016 Sep 20;7(38):61438-61457. doi: 10.18632/oncotarget.11367.
• [15] The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces. Br J Haematol. 2003 Jan;120(2):315-24. doi: 10.1046/j.1365-2141.2003.03971.x.
• [16] Mechanisms of tissue factor induction by the uremic toxin indole-3 acetic acid through aryl hydrocarbon receptor/nuclear factor-kappa B signaling pathway in human endothelial cells. Arch Toxicol. 2019 Jan;93(1):121-136.
• [17] Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation. 2000 May 15;69(9):1830-6. doi: 10.1097/00007890-200005150-00017.
• [18] Resveratrol and quercetin down-regulate tissue factor expression by human stimulated vascular cells. J Thromb Haemost. 2003 May;1(5):1089-95. doi: 10.1046/j.1538-7836.2003.00217.x.
• [19] Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
• [20] Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia. 1999 Jul;13(7):1062-70. doi: 10.1038/sj.leu.2401448.
• [21] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.